Tobias Neff

Merck & Co., Inc., Rahway, NJ, USA (United States) — United States

Medicine · Health Sciences

31h-index3.4kcitations103works3.22yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Acute Myeloid Leukemia Research(22), Virus-based gene therapy research(21), Epigenetics and DNA Methylation(18), RNA Interference and Gene Delivery(13), Intravenous Infusion Technology and Safety(12)

Publications103 total

P3.18.73 A Phase 1b/2 Study of Gocatamig and Ifinatamab Deruxtecan for Relapsed or Refractory Extensive-Stage Small Cell Lung Cancer
Journal of Thoracic Oncology·2025
Randomized, double-blind, phase III LEAP-003 study of first-line lenvatinib plus pembrolizumab versus placebo plus pembrolizumab for unresectable or metastatic melanoma
Annals of Oncology·2025· 4 cited
GATA2 links stemness to chemotherapy resistance in acute myeloid leukemia
Blood·2025· 11 citedOpen Access
Aberrant Stemness Transcription Signature Unveils a Mechanism of Chemotherapy Resistance through Blunting p53-Mediated Response in Acute Myeloid Leukemia
Blood·2024
385 Role of micropeptide beta cell and neural cell regulin in CF-related diabetes
Journal of Cystic Fibrosis·2024
Lenvatinib (len) plus pembrolizumab (pembro) in patients with advanced melanoma that progressed on anti–PD-(L)1 therapy: Over 4 years of follow-up from the phase 2 LEAP-004 study.
Journal of Clinical Oncology·2024· 4 cited
Phase 1 study of GSK3368715, a type I PRMT inhibitor, in patients with advanced solid tumors
British Journal of Cancer·2023· 65 citedOpen Access
The Role of GATA2 in Drug Resistance in AML
Blood·2022
Improved outcomes in proximal gastric bypass surgery following the transition from a conventional circular stapling to an augmented linear stapling protocol
British journal of surgery·2022
Inhaled Sedation in Patients with COVID-19-Related Acute Respiratory Distress Syndrome: An International Retrospective Study
2022
Evaluation of Cardiac Repolarization in the Randomized Phase 2 Study of Intermediate- or High-Risk Smoldering Multiple Myeloma Patients Treated with Daratumumab Monotherapy
Advances in Therapy·2021· 3 citedOpen Access
Epigenetic regulation of protein translation in KMT2A-rearranged AML
Experimental Hematology·2020· 14 citedOpen Access
Daratumumab monotherapy for patients with intermediate-risk or high-risk smoldering multiple myeloma: a randomized, open-label, multicenter, phase 2 study (CENTAURUS)
Leukemia·2020· 91 citedOpen Access
Epigenetic regulation of protein translation in <i>KMT2A</i> -rearranged AML
2019Open Access
Updated Results from the Phase 2 Centaurus Study of Daratumumab (DARA) Monotherapy in Patients with Intermediate-Risk or High-Risk Smoldering Multiple Myeloma (SMM)
Blood·2018· 8 cited
Activating PAX gene family paralogs to complement PAX5 leukemia driver mutations
PLoS Genetics·2018· 6 citedOpen Access
DOT1L (DOT1 like histone H3K79 methyltransferase)
Atlas of Genetics and Cytogenetics in Oncology and Haematology·2018Open Access
AMPK/FIS1-Mediated Mitophagy Is Required for Self-Renewal of Human AML Stem Cells
Cell stem cell·2018· 295 citedOpen Access
Randomized, open-label, phase 3 study of subcutaneous daratumumab (DARA SC) versus active monitoring in patients (Pts) with high-risk smoldering multiple myeloma (SMM): AQUILA.
Journal of Clinical Oncology·2018· 11 cited
MLL2, Not MLL1, Plays a Major Role in Sustaining MLL-Rearranged Acute Myeloid Leukemia
Cancer Cell·2017· 91 citedOpen Access
page 1 of 6Next →

Frequent Co-authors

Hans‐Peter Kiem(10), Scott A. Armstrong(7), Kathrin M. Bernt(7), Laura J. Peterson(6), Brian C. Beard(6), Peter A. Horn(5), Jesse Thompson(5), Simone S. Riedel(5), Stuart H. Orkin(4), Nan Zhu(4), C. Anthony Blau(4), Bobbie Thomasson(4), Joachim E. Fischer(4), Markus Weiß(4), Taylor Yamauchi(4), Jessica N. Haladyna(4), Huafeng Xie(3), Peter M. Voorhees(3), Hartmut Goldschmidt(3), Steven Kuppens(3)